{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T05:04:01Z","timestamp":1779685441382,"version":"3.53.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>With the rapid development of molecular biotechnology and in-depth exploration of bladder cancer (BC) oncogenic mechanisms, targeted therapy has emerged as a pivotal treatment modality for BC patients. This study employed bibliometric methods to analyze the research status and development trends of targeted therapy in BC both domestically and internationally, aiming to identify research hotspots and provide a reference for research layout in this area.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was conducted across renowned international and domestic databases, including Web of Science Core Collection (WoSCC), PubMed, Wanfang Database, and the Chinese National Knowledge Infrastructure (CNKI). The search period was limited to 1994\u20132024, with search terms including \u201cbladder cancer\u201d, \u201ctargeted therapy\u201d, and their related derivatives. After screening, 912 English publications and 328 Chinese publications were included. WPS Excel (v12.1.0) was used to visualize trends in annual publication volume, and CiteSpace (v6.3.R1) was employed for a visual analysis of countries\/regions, institutions, authors, journals, cited articles, and keywords related to the included publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the field of targeted therapy in BC, the annual publication volume has generally shown an upward trend over the past three decades for both English and Chinese publications, with a faster growth rate observed in English publications. For English publications, the most productive countries\/regions, institutions, authors, and journals were the USA, University of Texas System, Dinney CPN, and Urologic Oncology\u2014Seminars and Original Investigations, respectively. The most cited article was \u201cComprehensive Molecular Characterization of Urothelial Bladder Carcinoma\u201d published in\n                      <jats:italic>Nature<\/jats:italic>\n                      . A cluster analysis of keywords revealed research hotspots such as \u201cphase-ii trial\u201d, \u201ccell line\u201d, and \u201cEGF receptor\u201d. For Chinese publications, the most productive institutions, authors, and journals were the Second Hospital of Jilin University, Wang JS, and Chinese Journal of Urology, respectively. The most cited article was \u201cAdvances in the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer\u201d published in Shandong Medical Journal. The cluster analysis of keywords identified research hotspots including \u201cmigration\u201d, \u201ccell proliferation\u201d, and \u201cdrug resistance\u201d.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Currently, Europe and America dominate the field of targeted therapy in BC. China can leverage its advantage in terms of patient population size to strengthen domestic and international collaborations, thereby enhancing its research influence in this field. Global research hotspots reveal the translational process of targeted therapy in BC from bench to bedside. Future research in this field will focus on drug management of targeted therapy for metastatic BC and overcoming drug resistance to targeted therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1850175","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T04:44:58Z","timestamp":1779684298000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The international and domestic research trends of targeted therapy in bladder cancer: a bibliometric analysis of the past three decades"],"prefix":"10.3389","volume":"16","author":[{"given":"Yijin","family":"Pan","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binbin","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinqiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B2","volume-title":"AJCC Cancer Staging System: Anus. 9th Version","author":"Goodman","year":"2022"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217676","article-title":"Apigenin inhibits recurrent bladder cancer progression by targeting VEGF-\u03b2","volume":"620","author":"Shi","year":"2025","journal-title":"Cancer Lett"},{"key":"B4","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.12.002S","article-title":"The financial burden of localized and metastatic bladder cancer","volume":"87","author":"Scilipoti","year":"2025","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15225490","article-title":"A clinical viewpoint on the use of targeted therapy in advanced gastric cancer","volume":"15","author":"Sk\u00f3rzewska","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000492","article-title":"Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis","volume":"109","author":"Jiang","year":"2023","journal-title":"Int J Surg"},{"key":"B10","article-title":"CiteSpace II: visualization and knowledge discovery in bibliographic databases","volume":"2005","author":"Synnestvedt","year":"2005","journal-title":"AMIA Annu Symp Proc"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1474496","article-title":"Global research trends and frontiers in ferroptosis in hepatocellular carcinoma: a bibliometric and visualization study","volume":"14","author":"Ning","year":"2024","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101059","article-title":"Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer","volume":"73","author":"Li","year":"2024","journal-title":"Drug Resist Update"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-025-01645-7","article-title":"Advancements in the diagnosis, treatment, and risk stratification of non-muscle invasive bladder cancer","volume":"27","author":"Smani","year":"2025","journal-title":"Curr Oncol Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2174\/187152012803529673","article-title":"Targeted therapy for advanced urothelial cancer of the bladder: where do we stand","volume":"12","author":"Zhu","year":"2012","journal-title":"Anti-Cancer Agents Med Chem"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12602","article-title":"FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies","volume":"44","author":"Noeraparast","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11523-024-01119-z","article-title":"FGFR-altered urothelial carcinoma: resistance mechanisms and therapeutic strategies","volume":"20","author":"Benjamin","year":"2025","journal-title":"Target Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12935-024-03597-7","article-title":"Mechanistic insights of lenvatinib: enhancing cisplatin sensitivity, inducing apoptosis, and suppressing metastasis in bladder cancer cells through EGFR\/ERK\/P38\/NF-\u03baB signaling inactivation","volume":"25","author":"Chiang","year":"2025","journal-title":"Cancer Cell Int"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1158\/2159-8290.CD-22-1441","article-title":"Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer","volume":"13","author":"Facchinetti","year":"2023","journal-title":"Cancer Discov"},{"key":"B19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.juro.2014.07.121","article-title":"The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidence","volume":"193","author":"Mooso","year":"2015","journal-title":"J Urol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1101\/gad.13.12.1501","article-title":"CDK inhibitors: positive and negative regulators of G1-phase progression","volume":"13","author":"Sherr","year":"1999","journal-title":"Genes Dev"},{"key":"B21","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1158\/1078-0432.CCR-18-0685","article-title":"CDK4\/6 inhibitor as a novel therapeutic approach for advanced bladder cancer independently of RB1 status","volume":"25","author":"Rubio","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B23","article-title":"Experimental study on adenovirus-mediated thymidine kinase gene therapy for bladder cancer regulated by human telomerase reverse transcriptase promoter","author":"Wang","year":"2005","journal-title":"Chin J Urol"},{"key":"B24","article-title":"Effects of survivin small Interfering RNA on biological behavior of bladder cancer T24 cells","author":"Wang","year":"2008","journal-title":"Chin J Cancer"},{"key":"B25","article-title":"Screening of bladder cancer-specific binding peptides using in vivo phage display technology","volume":"31","author":"Luo","year":"2015","journal-title":"Chin J Immunol"},{"key":"B26","article-title":"Inhibition of miR-130b-3p suppresses bladder cancer cell proliferation by upregulating PTEN and inactivating PI3K-AKT and integrin \u03b21\/FAK signaling pathways","volume":"33","author":"Lyu","year":"2017","journal-title":"Chin J Biochem Mol Biol"},{"key":"B27","first-page":"45","article-title":"Expression of miR-372-3p in bladder cancer tissues and Its effects on proliferation, migration and invasion of bladder cancer cells","volume":"25","author":"Zhang","year":"2018","journal-title":"Chin J Cancer Biother"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21631","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: A review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.003","article-title":"Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial","volume":"35","author":"Siefker-Radtke","year":"2024","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma","volume":"34","author":"Rosenberg","year":"2023","journal-title":"Ann Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511648","article-title":"Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer","volume":"393","author":"Sheng","year":"2025","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13046-019-1089-z","article-title":"New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment","volume":"38","author":"Criscuolo","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0336","article-title":"Rapamycin prevents surgery-induced immune dysfunction in patients with bladder cancer","volume":"7","author":"Svatek","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-71327-w","article-title":"Miniature and versatile genome regulation TnpB-\u03c9RNA toolkits facilitate cancer immunotherapy","author":"Lu","year":"2026","journal-title":"Nat Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.14440\/bladder.2024.0044","article-title":"Advancements in genetic circuits as part of intelligent biotherapy for the treatment of bladder cancer: A review","volume":"12","author":"Liu","year":"2025","journal-title":"Bladder (San Franc)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"7983","DOI":"10.1038\/s41467-025-63377-3","article-title":"Reprogramming the tumor microenvironment with c-MYC-based gene circuit platform to enhance specific cancer immunotherapy","volume":"16","author":"Zhan","year":"2025","journal-title":"Nat Commun"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1850175\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T04:45:08Z","timestamp":1779684308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1850175\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":38,"alternative-id":["10.3389\/fonc.2026.1850175"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1850175","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"article-number":"1850175"}}